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ABSTRACT  
Inter-individual susceptibility to mutagens/carcinogens can be assessed by either 
genotyping DNA repair genes in different pathways or phenotyping DNA repair capacity 
(DRC) at the molecular or cellular level. Due to the large number of known DNA repair 
genes, and the interactions between repair pathways, phenotyping is becoming the preferred 
approach to measure DRC, and reliable assays are therefore increasingly needed. The use of a 
cellular phenotype comet assay for the nucleotide excision repair (NER) pathway using 
benzo[a]pyrene diol epoxide (BPDE) has been described in previous papers, but no thorough 
evaluation of its applicability in large genotype-phenotype studies has been presented.  
Our aim was to evaluate the possibility of using cryopreserved instead of fresh peripheral 
blood mononuclear cells (PBMCs) to evaluate intra- and inter-assay variation, and inter-
individual variation, for the aphidicolin (APC)-block NER comet assay. Moreover, we 
measured the variation for the designated internal standard (K562 erytroleukemia cell line) 
and we evaluated the feasibility to use lymphoblastoid cell lines (LCLs) as surrogate of 
PBMCs. 
Our results showed a low intra- (coefficient of variation [CV] 19.9%) and inter-assay (CV 
32.3%) variation, with a good inter-individual variation (122 subjects, mean ± standard 
deviation 7.38 ± 4.99; range 0.66-26.14; CV 67.63%). A significant correlation between 
results derived from cryopreserved and fresh PBMCs from the same individuals was found 
(10 subjects, r = 0.62; p = 0.05). Results from LCLs and cryopreserved PBMCs from the 
same subjects showed an inverse significant correlation (10 subjects, r = -0.712 p = 0.02). 
K562 cells as internal standard showed low intra-assay variation.  
In the present study the APC-block NER comet assay on cryopreserved PBMCs seemed to be 
a reliable method to measure DRC variation in epidemiological studies; LCLs were not a 
good surrogate in this assay.  
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INTRODUCTION  
Less efficient DNA repair capacity (DRC) is associated with increased cancer risk and 
other human diseases, such as neurodegenerative disorders, inflammatory disorders and 
ageing. DRC is an ubiquitous defense mechanism that plays an essential role in cell survival 
and genome stability (1). Moreover, it is an important factor of inter-individual variation in 
response to mutagen exposure and cancer susceptibility (2). Cells have developed a network 
of DNA repair mechanisms to ensure that the large variety of DNA lesions induced by 
exogenous and endogenous sources are effectively dealt with. At least five partly overlapping 
main repair pathways are active in the removal of DNA lesions: base excision repair (BER), 
nucleotide excision repair (NER), mismatch repair (MMR), double strand break repair 
(DSBR) and direct repair (DR) (1,3). The development and validation of functional assays 
that are able to assess individual DRC is notably important for identifying high-risk complex-
disease susceptible subgroups within the general population (4).  
The alkaline comet assay is a relatively inexpensive technique for the detection of DNA 
damage and repair. Since few cells are required for the assay, it is particularly advantageous 
for the analysis of human samples. The method has proven to be very sensitive, and can detect 
small phenotypic changes caused by genetic variation (5). An interesting possible 
epidemiological application of the assay is the determination of inter-individual variation in 
DRC (6). Most alkaline comet assay protocols used in biomonitoring employ peripheral blood 
mononuclear cells (PBMCs), in part because obtaining blood from human subjects is 
minimally invasive. However, the technical and logistical difficulties that arise when working 
with fresh PBMCs have rendered their use quite challenging in epidemiological studies of 
DRC, and no refined protocol exists for the use of viable cryopreserved PBMCs. In fact, 
previous papers have been published on the use of human PBMC extracts deriving from 
PBMC frozen at -80 ⁰C (7), from cryopreserved PBMCs (8,9) or from dry PBMC pellets 
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(10,11). These in vitro assays consist of an incubation of lymphocyte extracts with substrate 
nucleoid DNA from cells pretreated with specific damaging agent: either photosensitizer plus 
light to induce 8-oxoguanine (8,9), or short wavelength ultraviolet light irradiation (7), or 
benzo[a]pyrene diol epoxide (BPDE) (10,11). The advantage of this kind of in vitro repair 
assays is that they use DNA substrates with few lesions that simulate the in vivo asset. 
However, the above assays have also some limitations due to imbalance between 
concentration in protein extracts, enzyme activity and substrate amount as well as in setting 
the right incubation time. Moreover, this kind of assays do not always allow discrimination 
between DNA breaks induced by the mutagen and those resulting from DNA repair incisions, 
or do not assess a cellular phenotype, but instead measure DRC in cell extracts. Standard 
cellular “challenge” assays using viable cells have the advantage that the endpoint is the 
removal of the lesions and restoration of normal DNA structure (4), but they require the 
sampling at several time-points. In our method we simplified the assay by adding the DNA 
polymerase inhibitor aphidicolin (APC) (12).  
The APC-block NER comet assay is a cellular phenotype assay that measures DRC after 
BPDE treatment as model mutagen, and has already been developed and validated on fresh 
PBMCs by Vande Loock et al. (12). In the present study we validated the assay on 
cryopreserved PBMCs by comparing DRC in fresh and cryopreserved PBMCs, evaluating 
intra- and inter-assay variation and standardizing the use of an internal control to minimize 
the variation between different electrophoretic runs. Moreover, to evaluate inter-individual 
variation we performed the assay on a larger number of subjects. 
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MATERIALS AND METHODS 
 
Lymphocyte isolation 
PBMCs were separated from heparinized venous blood collected from healthy subjects by 
centrifugation with Ficoll Paque PLUS (GE Healthcare, Milan, Italy) at 400 x g for 30 
minutes at room temperature. After two washes in a combination of RPMI 1640, 1% FBS and 
25 mM EDTA, PBMCs were prepared for cryopreservation. Cells were resuspended at 
10x10
6
 cells/ml in freezing medium (RPMI 1640, 50% FBS, 10% DMSO), aliquoted in 
cryovials and slowly frozen overnight at the rate of –1ºC/minute in isopropyl alcohol to –80ºC 
(Mr. Frosty containers, Nalgene, Roskilde, Denmark). Cryovials were then transferred into 
liquid nitrogen for long-term storage. All PBMCs used in the present study were 
cryopreserved before use, unless otherwise stated. Cells were stored in liquid nitrogen for a 
period ranging from one month to a maximum of one year.  
 
Lymphoblastoid cell lines  
Lymphoblastoid cell lines (LCLs) were derived from the PBMCs of 10 healthy subjects as 
previously described (13,14), and cryopreserved in the laboratory of the University of Turin. 
Briefly, an aliquot of PBMCs was incubated in RPMI 1640 medium supplemented with L-
glutamine, 100 μg/ml streptomycin and 100 U/ml penicillin and 10% FBS (complete medium) 
for 15 h at 37°C and 5% CO2, in the presence of EBV-containing supernatant (from B95-8 
marmoset lymphoma cells, ATCC, Washington, DC, cat. no. CRL-1612) 1:1 (v/v). The cells 
were then washed and cultured (1.5x10
6
/ml) in complete medium in the presence of irradiated 
(30 Gy) allogenic PBMCs (0.5x10
6
/well) and 0.5 μg/ml cyclosporin A (Sigma Aldrich Italia, 
Milan, Italy). Cells were grown adding fresh medium every 3 days and fresh feeder cells after 
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one week. After 3-4 weeks, LCLs were established, and cells were cryopreserved as above 
described for fresh PBMC. Before performing the assay, cells were rapidly thawed and 
cultured in RPMI 1640, 10% FBS, 1% L-glutamine (Invitrogen, Carlsbad, CA), 1% Na-
pyruvate (Invitrogen), 1% non-essential amino acids (Invitrogen), 1% kanamycin 
(Invitrogen). NER comet assay results from LCLs were compared with those from PBMCs 
from the same subjects. NER comet assay was performed as described below: cells from the 
same subject (LCLs and PBMCs) were treated on the same day and analyzed in the same 
electrophoresis run to avoid further variation. 
 
Cell treatments 
Cryopreserved PBMCs were thawed quickly
 
in a 37°C water bath and suspended in 5 ml 
of medium at 4⁰C containing 50% FBS, 49% RPMI 1640 and 1% dextrose. Treatment was 
performed as previously described (12), with minor modifications. Cells were
 
spun down by 
centrifugation (10 minutes at 450 x g) at 4°C,
 
and 5x10
6
 viable cells were suspended in 5 ml 
of F10 medium (Invitrogen, Paysley, UK) containing 10% FBS and
 
2.5 µg/ml 
phytohemoagglutinin (PHA) (Sigma-Aldrich Co, St Louis, MO, USA). Twenty-four hours 
later,
 
samples were centrifuged (10 minutes at 450 x g) at 4°C,
 
and cell pellets were 
resuspended in 5ml of serum-free F10 medium  containing 2.5 µg/ml PHA. Cells were then 
aliquoted into 5 culture tubes for the following treatment conditions (tubes were named A, B, 
C, D, E for each sample): (A) F10 medium only; (B) 0.5% DMSO (solvent of APC and 
BPDE); (C) 2.5 µg/ml of APC (Sigma-Aldrich Co), added at time 0; (D) 0.5 µM BPDE (NCI 
Chemical Carcinogen Reference Standards Repository, Midwest Research Institute, Kansas 
City, MO, USA), added at time 30 min; (E) pretreatment with 2.5 µg/ml of APC (30 min) 
followed by 0.5 µM BPDE (2 hours). All the cell cultures were incubated for a total of 2.5 
hours at 37°C, 5% CO2. At the end of the treatment cells were centrifuged and pelleted cells 
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were processed for NER comet assay. When indicated, only the APC negative control was 
used (only treatments C, D and E were assayed for). 
LCLs were seeded into T25 flasks at a density of 5x10
5
 cells per ml and grown at 37°C at 
5% CO2 for 24 hours, then treated with the same procedure performed for cryopreserved 
PBMCs. 
 
Aphidicolin-block NER comet assay 
The NER comet assay was performed according to the methods described by Singh et al. 
(15) and Vande Loock et al. (12), with slight modifications. After treatment, cells were mixed 
with low-melting-point agarose (0.75%; Sigma-Aldrich Co) and layered on 85x100 mm 
GelBond films (Lonza, Basel, Switzerland). Each GelBond film comprised eight 19x23 mm 
agarose gels. The GelBond films were immersed in lysis solution (2.5 M NaCl, 0.1 mM 
Na2EDTA, 10 mM Tris, 1% Triton X-100, pH 10) for 1.5 hours at 4ºC, then placed in an 
electrophoresis tank for 40 minutes, submerged into electrophoresis buffer (0.3 M NaOH, 1 
mM Na2EDTA, approximately pH 13). Finally, gels were electrophoresed at 30 V (0.8 V/cm) 
and 300 mA for 20 minutes. After neutralization with 0.4 M Tris-HCl (pH 7.5) gels were 
fixed in ethanol and dried at room temperature. The nuclei were visualized by a Leica 
fluorescence microscope at 40X magnification and two gels of 50 nuclei for each sample 
treatment were scored with Comet IV software (Perceptive Instrument, Suffolk, UK). The 
median tail intensity fluorescence (% Tail DNA) of 100 nuclei was used as a measure of DNA 
damage. For each electrophoresis run, a human K562 erytroleukemia cell line was included as 
an internal standard and used to normalize results. DRC was calculated for each subject as: % 
Tail DNAAPC+BPDE - % Tail DNA BPDE - % Tail DNA APC. 
 
Variation in K562 cells as the internal standard 
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A human K562 erytroleukemia cell line was included as an internal standard in each of 
the electrophoretic runs to account for variations across different runs. As the variation of 
background DNA damage in permanent cultures of K562 cells can be very wide, in order to 
eliminate variation due to the culture and to limit the overall variation in the electrophoresis 
run, we prepared a batch of cryopreserved K562 cells as follows. K562 cells were cultured in 
suspension in RPMI 1640 medium supplemented with 10% FCS, glutamine and 
penicillin/streptomycin. Cultures were incubated at 37⁰C in 5% CO2 and supplied with new 
medium twice a week. A uniform batch of K562 cells was obtained by growing up to 50x10
6
 
cells and aliquoting them at 1x10
6 
cells/aliquot. All cells were cryopreserved the same day, 
and stored in liquid nitrogen until use. 
To evaluate background levels of DNA damage in K562 cells, and to assess intra-assay 
variation, we prepared 24 NER comet assay gels from one of the K562 aliquots: cells were 
extracted from liquid nitrogen and rapidly thawed at room temperature. Cells were mixed 
with low-melting-point agarose (0.75%; Sigma-Aldrich Co) and layered on 85x100 mm 
GelBond films (Lonza, Basel, Switzerland). Each GelBond film comprised four 19x23 mm 
agarose gels. Comet assay was performed as described in “Aphidicolin-block NER comet 
assay” paragraph. The procedure was repeated on 4 different days, to test for inter-assay 
variation. A total of 96 gels (24 gels for each day, repeated in 4 different days) were scored, 
including 50 nuclei each. The position of each slide in the electrophoretic tank was recorded, 
to control for position effects. All the gels were prepared by a single operator, who also 
performed NER comet assays. Coded gels were scored blindly twice, by two different 
operators. 
The batch of cryopreserved K562 cells was then used as the internal standard, with one 
K562 aliquot included in each electrophoresis run of assayed samples. NER comet assay 
scores were then normalized to those of the K562 cells used in the same electrophoresis run 
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by dividing TI values of samples with TI of K562 cells as suggested in (16). A reference 
value of the internal standard has been calculated to check whether outcomes from a given 
electrophoresis should be excluded from the analysis or not by using a similar approach as in 
(16). The mean±2 standard deviation (SD) of the TI of K562 cells was taken as reference. 
When internal standards values were lower or higher than this reference interval results of all 
samples included in the same electrophoresis run were excluded from the final analysis (16). 
In the present set of experiments no runs have been excluded from the analysis. 
 
DRC in fresh and cryopreserved PBMCs 
Comparison between fresh and cryopreserved PBMCs was performed on 10 subjects. 
PBMCs were isolated and cryopreserved as described above, while a part of them was 
immediately cultured with PHA for treatment of fresh PBMCs (see paragraph “Cell 
treatments”). 
 
Intra- and inter-assay variation 
Cryopreserved PBMCs from three healthy subjects were used to evaluate intra- and inter-
assay variation of the NER comet assay. Different aliquots of cryopreserved PBMCs were 
thawed on different days (inter-assay; donor 1: three experiments; donor 2: three experiments; 
donor 3: two experiments), and each aliquot was further divided into two different cell 
cultures for treatment (intra-assay). 
 
Inter-individual variation in DRC 
To evaluate inter-individual variation, NER comet assay was performed on PBMCs from 
122 young healthy subjects (39 males, 83 females; mean age 24.5 years, range 19.1–48.4 
years). Subjects provided written informed consent before inclusion in the present study. DRC 
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was calculated for each subject as explained below, and all values were normalized to the 
designated internal control (K562 cell aliquots prepared as cryopreserved batch with one 
aliquot thawed for each electrophoresis run, see above). 
To validate the applicability of the NER comet assay to the analysis of a large number of 
subjects, we also tested the use of only one negative control for each subject instead of three, 
in order to reduce the overall number of gels to be scored in a large study on DRC. After 
experimental validation of a correlation between the different negative control treatments on 
10 subjects, we performed the NER comet assay using APC as the only negative control, one 
single culture for each treatment and one aliquot from the same batch of cryopreserved K562 
cells for each electrophoresis run.  
 
Statistical analysis 
Mean of median values of % Tail DNA, SD and percentage of coefficient of variation 
(CV %) were used for a statistical description of data, and the Pearson coefficient was used 
for correlation assessment. 
Intra- and inter-assay analyses were performed with non-parametric tests (Kruskal Wallis 
and Wilcoxon signed rank test, as needed), with Bonferroni correction for multiple 
comparison. 
We analysed for variation in K562 cells across different testing days, within different 
positions in the electrophoretic tank, and by scorer using the Wilcoxon Rank Sum test, 
Wilcoxon Signed Rank test and Kruskal-Wallis test as appropriate. All analyses were 
conducted using SAS V 9.2. 
 
 
RESULTS 
 
Comparison of DRC between cryopreserved and fresh PBMCs  
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We performed NER comet assay with both fresh and cryopreserved PBMCs from 10 
healthy subjects and found a significant correlation between samples from the same subject (r 
= 0.62; p = 0.05, Figure 1). A very low DRC reflects in general a weak capacity to resolve the 
DNA damage, however, from a biological point of view (and from our formula), we should 
not expect negative values. On the other hand, a negative DRC could reflect a sensitivity 
limitation of the technique in measuring very low synthesis activity levels (Supplementary 
Table I). 
 
Intra- and inter-assay variation  
Optimal experimental set-up was chosen based on the validation previously described on 
fresh PBMCs (12). Intra- and inter-assay variation was measured and, no statistically 
significant differences were detected between the three repeated experiments (one day‟s 
results for Donor #3 are missing due to technical issues) for any of the three donors (nor 
between the two parallel cultures, data not shown), indicating low intra- and inter-assay 
variation (Table I, Supplementary Table II). CV % were between 5.12% and 44.10% for the 
intra-assay variation, and between 9.43% and 27.12% for the inter-assay variation. Intra-
culture variation CV % ranged from 0.33% to 71.24%. 
 
Inter-individual variation in DRC 
DRC as evaluated in 122 healthy subjects by comet assay on PBMCs to measure inter-
individual variation (median % Tail DNA) showed a CV% of 67.63%, with a broad range 
from 0.66 to 26.14 and a mean ± SD of 7.38 ± 4.99 (Supplementary Table III). Five to seven 
subjects were examined every day, for a total of 18 different experiments; K562 internal 
standard mean of median % Tail DNA was 8.41 ± 4.09. 
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Our experimental validation of the correlation between the different negative control 
treatments we performed in the NER comet assay showed a significant positive correlation 
between the three treatments used as negative controls (background, solvent and APC): 
solvent versus background (r = 0.80, p = 0.006); solvent versus APC (r = 0.84, p = 0.003); 
background versus APC (r = 0.71, p = 0.022). These results suggest it might be possible to 
use just one negative control when testing cryopreserved PBMCs, which has already been 
proposed for fresh PBMCs (12).This last approach was adopted in the present study when 
measuring inter-individual variation. 
 
K562 cell variation as an internal standard 
As the variation of background DNA damage in permanent cultures of K562 cells can be very 
wide (16), we prepared a batch of cryopreserved K562 cells in order to eliminate variation 
due to cell cycle in the culture, thus limiting the overall variation in the electrophoresis run. 
No statistically significant difference was evident across different operator scoring, testing 
days, or different electrophoresis positions (Supplementary Table IV).  
 
Comparison between LCLs and PBMCs 
We performed NER comet assay on both LCLs and PBMCs from 10 subjects to evaluate 
the suitability of LCLs as a surrogate tissue (Supplementary Table V). Figure 2 shows the 
comparison of DRC measured in the two cell types. LCLs show a lower DRC (mean ± SD: 
4.30 ± 4.07) than PBMCs (9.73±3.51), with a statistically significant inverse correlation (r = -
0.712; p = 0.02). Moreover LCLs showed a larger inter-individual variation (CV % 94.79) 
than PBMCs (CV % 36.11). 
 
DISCUSSION  
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The alkaline comet assay is a sensitive and relatively inexpensive technique for the 
detection of DNA damage and DNA repair (6). Often, the assay is performed on PBMCs as 
blood sampling is minimally invasive. However, the use of PBMCs to examine DRC in 
epidemiological studies is still challenging. Indeed, there are many technical and logistical 
difficulties related to the use of fresh lymphocytes, and there is no refined protocol for the use 
of viable cryopreserved PBMCs. 
Samples are usually collected over an extended period of time, and DRC can either be 
analyzed immediately after sampling, or retrospectively. The most efficient approach when 
using comet assay is generally a retrospective analysis using cryopreserved cells. This reduces 
any possible inter-batch variation by running more samples in the same experiment.  
Recent studies have examined the inter-assay experimental variation of the comet assay 
(17,18), but only a few compared fresh and cryopreserved PBMCs. Trzeciak et al. showed 
that cryopreserved PBMCs can be used to measure DNA repair after treatment with γ 
radiation: DRC was assessed in a small cohort (10 subjects) measuring initial DNA damage, 
half-time of DNA repair and residual damage after 30 and 60 min (19). Duthie et al. evaluated 
in PBMCs the effect of cryopreservation on the measurement of endogenous and induced 
DNA strand breakage, altered bases, antioxidant capacity following incubation with the 
dietary flavonoid quercetin, and DRC. The authors demonstrated that frozen human 
lymphocytes can be suitable for most aspects of the detection of biomarkers of DNA damage, 
but not for oxidant-induced DNA strand break repair (20). 
The objective of the present study was to validate the use of an APC-block NER comet 
assay on cryopreserved PBMCs and to show the assay‟s reliability and applicability to a large 
number of samples. This modified comet assay is based on the assessment of cellular DNA 
damage repair, and measures the capacity of donor cells to resolve DNA damage in case of in 
vitro challenging with BPDE in the presence or absence of APC, a potent and specific 
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inhibitor of DNA polymerases α and δ (21). The method has already been standardized on 
fresh PBMCs (12), and we then applied to cryopreserved PBMCs using K562 cells as an 
internal standard to avoid experimental variation during electrophoretic runs (16). With the 
present assay is possible to evaluate the number of damaged sites produced by NER incision 
that have been repaired after 2h BPDE exposure. This is a reflection also of the synthesis 
activity. Since it is not possible to distinguish the origin of DNA damage not repaired (if basal 
or induced by the treatment), some further improvements of the assay are needed in the future 
(i.e. BPDE treatment at different time). 
Firstly, we compared DRC measured in fresh and cryopreserved PBMCs from 10 donors. 
As a significant correlation was found (r = 0.62, p = 0.05), we further validated the assay on 
cryopreserved PBMCs evaluating intra- and inter-assay variation. We obtained DRC CVs % 
(mean intra-assay CVs % for each donor) ranging from 14.2% to 35.1% for intra-assay 
variation, and from 9.4% to 27.1% for inter-assay variation. These ranges of variation are 
quite similar to those previously reported for fresh PBMCs (12).  
To evaluate the suitability of NER comet assay to assess inter-individual variation in 
DRC, we performed the assay on cryopreserved PBMCs collected from 122 young healthy 
subjects. In this case, DRC ranged from 0.66 to 26.14, with a CV % of 67.6%. These results 
suggest that the methodology has the capacity to detect inter-individual variation in 
cryopreserved PBMCs as in fresh PBMCs, showing intra-individual, intra- and inter-assay 
variation that are lower than the inter-individual variability. Many studies during the last few 
years have analyzed the NER inter-individual variations in healthy individuals. Qiao et al. 
found a NER capacity variation of 4-7 times, measured by host cell reactivation assay 
(HCRA) in 102 healthy subjects (22). Tyson et al. showed an inter-individual variation of 11 
times in the NER capacity, always measured by HCRA in 66 healthy young individuals (23). 
Moreover, the repair activity induced by UV ray damage, measured by unscheduled DNA 
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synthesis, varied with a range of approximately 8 times in healthy control subjects. The 
explanations of a substantial inter-individual variation in the ability to repair the DNA can 
include genetic factors, as polymorphisms of DNA repair genes and environmental factors, as 
diet and life style. Recently Slyskova et al. analyzed DRC in 100 healthy subjects by BPDE-
challenge comet assay (24). They observed that the levels of single strand breaks that 
represents NER-mediated breaks originated from BPDE-adducts removal varied from 0 to 76 
Tail DNA %. In our sample population, we observed a range of variability of about 40 times 
in inter-individual DRC. The wider range of variability observed by Slyskova et al. could be 
due to the different endpoint of their method and to the different BPDE treatment (i.e. 
different concentration) they applied. 
To adapt the assay to the analysis of large sample sizes such as those regarding molecular 
epidemiological studies, we tried to reduce the burden of the work required by the assay itself, 
and evaluated the correlation between different negative controls usually included in each 
assay, with the final goal of selecting the most suitable for our purposes. We obtained a high 
correlation between solvent (DMSO) and background (r = 0.79, p = 0.006), background and 
APC (r = 0.71, p = 0.02) and solvent and APC (r = 0.84, p = 0.003). These results confirmed 
those obtained with fresh PBMCs (12), suggesting that it might be possible to choose only 
one treatment as a negative control for experiments on a large number of samples. 
To account for inter-electrophoresis differences, a K562 erythroleukemia cell line was 
used as the internal standard (16). This allowed for the comparison of several different 
electrophoresis sessions, which are necessary when a large number of samples is processed. 
Nevertheless, the use of this particular cell line may not be completely straightforward, as the 
cell line genotype/genome may not be entirely stable. This may cause heterogeneity in the 
evaluation of DNA damage. In the present study we reduced the variation in the internal 
standard itself by preparing a large batch of cryopreserved cells from the same culture and 
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storing them immediately after. Moreover, we examined the variation of internal standard gels 
run in different positions of the electrophoretic tank, and variation in operator scoring. There 
were no statistically significant differences among the positions in the electrophoretic tank or 
between scores given by different operators, nor there was significant inter-day variation. 
Finally, when we used the K562 cell batch for inter-individual DRC analysis, performing 18 
different experiments, K562 internal standard mean of median % Tail DNA ± SD was 8.41 ± 
4.09, fully comparable with the results reported by De Boeck et al. (16). 
The use of LCLs a surrogate of PBMCs for DRC evaluation has been previously tested 
(25-28). In the present study we performed the NER comet assay on LCLs obtained from 10 
subjects and their corresponding cryopreserved PBMCs to evaluate whether LCLs were 
suitable as a surrogate tissue. In agreement with our previous findings on other DNA repair 
assays (13,14), LCLs are not a suitable surrogate of PBMCs for NER comet assay, since they 
showed a negative correlation with DRC obtained in corresponding PBMCs and a very high 
inter-individual variation. This result may be due to the genomic instability and DNA repair 
inhibition induced by Epstein-Barr virus (29). 
The use of the NER comet assay on cryopreserved PBMCs to measure DRC in 
epidemiological studies is further supported by the possibility to use one, instead of three, 
negative controls, allowing for the analysis of a large number of samples simultaneously, and 
by the normalization to a K562 cell standard, that allows for comparison between different 
electrophoretic runs. 
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FIGURE LEGENDS 
 
 
Fig. 1 
Correlation between fresh and cryopreserved peripheral blood mononuclear cells (PBMCs) in 
ten subjects (DRC: DNA repair capacity). 
 
Fig. 2 
Comparison of DNA repair capacity (DRC) evaluated in lymphoblastoid cell lines (LCLs) 
and peripheral blood mononuclear cells (PBMCs) obtained from ten subjects. 
 
